FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $402.8M | ||||
Company | Location | Date | Amt. (M) | Details |
Abcellute Ltd. | Cardiff, UK | 12/12** | £0.4 ($0.817) | Abcellute raised $816,717 through a private financing |
ACE Biosciences A/S | Odense, Denmark | 12/26** | €11.9 ($17.1) | ACE raised $17.1M in a new investment round |
Agile BioPharma Inc. | Princeton, N.J. | 12/20 | $5.6 | Agile raised $5.6M in an extension of its Series E financing round, bringing the total of the round to $17.6M; investors were the Hillman Company, ProQuest Investment, TL Ventures and Novitas Capital |
Ascendis Pharma A/S | Copenhagen, Denmark | 12/13 | DKK17.6 ($25.7) | Ascendis raised $25.7M in a Series A round led by Sofinnova Partners and co-led by Gilde Healthcare Partners, with participation by Zweite TechnoStart Ventures Fonds GmbH & Co. KG |
Asuragen Inc. | Austin, Texas | 12/10 | $18.5 | Asuragen raised $18.5M in a Series B round; investors included PTV Sciences, Telegraph Hill Partners and Growth Capital Partners |
Carigent Therapeutics Inc. | New Haven, Conn. | 12/11 | $2 | Carigent secured $2M in a Series A financing from Saint Simeon Marketing and Investments |
Cogentus Pharmaceuticals Inc. | Menlo Park, Calif. | 12/20 | $62.5 | Cogentus raised $62.5M to support development of its antiplatelet therapy CGT-2168; the Series C financing was led by the Keffi Group, with participation from Prospect Venture Partners, Ridgeback Capital, Apothecary Capital and Pinnacle Ventures |
Corthera Inc. | San Mateo, Calif. | 12/20 | $23 | Corthera closed a $23M Series C financing; new investor Caxton Advantage Life Sciences Fund joined Domain Associates and Kleiner, Perkins, Caufield & Byers in the financing round |
Deltanoid Pharmaceuticals Inc. | Madison, Wis. | 12/18 | $12 | Deltanoid raised $12M in a Series B financing led by the Wisconsin Alumni Research Foundation that included Mason Wells and Venture Investors LLC, undisclosed corporations,-company founders and angel investors |
Fovea Pharmaceuticals SA | Paris | 12/12 | €30 ($44) | Fovea raised $44M in a Series B round led by Forbion Capital Partners; they were joined by Sofinnova Partners, Abingworth, GIMV, the WellCome Trust and Credit Agricole Private Equity |
Fundamental Applied Biology | Menlo Park, Calif. | 12/10 | $21 | Fundamental Applied Biology raised $21M in a Series B round co-led by SV Life Sciences and Alta Partners |
Innocoll Inc. | Ashburn, Va. | 12/17 | $30 | Innocoll raised $30M through a placement of convertible preferred stock; the financing was led by Camulos Capital LP, NewSmith Asset Management LLP and Morgan Stanley & Co. Inc. |
LineaGen Inc. | Salt Lake City | 12/19 | $5.8 | LineaGen closed a $5.8M Series A round led by vSpring Capital and Sanderling Biomedical Ventures, with participation by Mesa Verde Venture Partners |
Lytix Biopharma | Tromso, Norway | 12/20 | NOK50 ($8.9) |
Lytix raised $8.9M in a placement oversubscribed by Norwegian institutional and private investors |
Pantec Biosolutions AG | Ruggell, Liechtenstein | 12/12** | CHF6.3 ($5.6) | Pantec raised $5.6M in a first closing of a Series A round |
Pharnext | Paris | 12/12** | €2.5 ($3.68) | Pharnext raised $3.68M in seed funding from Truffle Capital |
PregLem SA | Geneva | 12/4 | CHF36 ($32.2) | PregLem closed a Series B round led by Sofin-nova Ventures, with participation from returning investors Sofinnova Partners, MVM Life Science Partners LLP and NeoMed Management |
Revance Therapeutics Inc. | Mountainview, Calif. | 12/12 | $43.2 | Medicis made a $20M equity investment in Revance as part of the Series C financing; other investors were Essex Woodlands, Healthcare Ventures, Vivo Ventures, Technology Partners Shepherd Ventures and Palo Alto Investors; Leerink Swann LLC acted as sole placement agent |
Santaris Pharma AS | Horsholm, Denmark | 12/18 | €20.4 ($29.4) | Santaris raised $29.4M in an investment round led by Gilde Healthcare Partners BV |
TcLand Expression SA | Paris | 12/19** | €8.2 ($11.8) | TcLand raised $11.8M in a Series A round led by Auriga Partners, and included investments by the Quest for Growth Privak fund managed by Quest Management NV, Beviguen, Debiopharm Group and Genzyme Ventures |
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. ND = Not disclosed. |
To read more on related topics, click on one of the words below.